Amyloid-β peptide (Aβ), a major pathological factor of the AD brain,17 and amylin share several features, including binding to the amylin receptor.18 Recent preclinical studies19,20,21 demonstrated that peripheral treatment of amylin or its analog reduces amyloid burden, tauopathy, and neuroinflammation in the AD brain. Here, IAPP is linked to tauopathy.